论文部分内容阅读
目的 比较MVP方案与CAP方案对晚期非小细胞肺癌 (NSCLC)的疗效和毒性。方法 分析MVP(丝裂霉素、长春花碱酰胺、顺铂 )方案及CAP(环磷酰胺、阿霉素、顺铂 )方案治疗 6 8例NSCLC的临床资料。结果 MVP组有效率为 40 .6 % ,其中完全缓解 2例 ;CAP组有效率为 2 7.8%。毒性反应主要为骨髓抑制及胃肠道反应。结论由丝裂霉素、长春花碱酰胺、顺铂组成的化疗方案治疗NSCLC的疗效较高 ,且毒性较小 ,患者可以耐受 ,是临床上切实可行的有效方案。
Objective To compare the efficacy and toxicity of MVP and CAP regimens for advanced non-small cell lung cancer (NSCLC). Methods The clinical data of MVP (mitomycin, vinblastine amide, cisplatin) and CAP (cyclophosphamide, doxorubicin, and cisplatin) regimens were analyzed in 68 NSCLC patients. Results The effective rate of MVP group was 40.6%, of which 2 cases were completely relieved; the effective rate in CAP group was 27.8%. The toxicities were mainly myelosuppression and gastrointestinal reactions. Conclusion The chemotherapy regimen composed of mitomycin, vinblastine amide and cisplatin has a higher curative effect on NSCLC with less toxicity and can be tolerated by patients. It is a clinically feasible and effective program.